Your browser doesn't support javascript.
loading
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Gao, Qiong; López-Knowles, Elena; U Cheang, Maggie Chon; Morden, James; Ribas, Ricardo; Sidhu, Kally; Evans, David; Martins, Vera; Dodson, Andrew; Skene, Anthony; Holcombe, Chris; Mallon, Elizabeth; Evans, Abigail; Bliss, Judith M; Robertson, John; Smith, Ian; Martin, Lesley-Ann; Dowsett, Mitch.
Afiliación
  • Gao Q; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.
  • López-Knowles E; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.
  • U Cheang MC; Ralph Lauren Centre for Breast Cancer Research.
  • Morden J; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Ribas R; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Sidhu K; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.
  • Evans D; Ralph Lauren Centre for Breast Cancer Research.
  • Martins V; Ralph Lauren Centre for Breast Cancer Research.
  • Dodson A; Ralph Lauren Centre for Breast Cancer Research.
  • Skene A; Ralph Lauren Centre for Breast Cancer Research.
  • Holcombe C; Royal Bournemouth Hospital, Bournemouth, UK.
  • Mallon E; Royal Liverpool University Hospital, Liverpool, UK.
  • Evans A; Queen Elizabeth University Hospital Glasgow, Govan, UK.
  • Bliss JM; Poole General Hospital, Dorset, UK.
  • Robertson J; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Smith I; University of Nottingham, Nottingham, UK.
  • Martin LA; Breast Unit, Royal Marsden Hospital, London, UK.
  • Dowsett M; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.
JNCI Cancer Spectr ; 2(2): pky005, 2018 Apr.
Article en En | MEDLINE | ID: mdl-31360844
To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor-positive (ER+) breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery from patients randomly assigned to receive either two weeks of presurgical aromatase inhibitor (AI; n = 157) or no presurgical treatment (n = 56). Those genes most markedly altered in the AI group (eg, FOS, DUSP1, RGS1, FOSB) were similarly altered in the no treatment group; some widely investigated genes that were apparently unaffected in the AI group (eg, MYC) were counter-altered in the control group, masking actual AI-dependent changes. In the absence of a control group, these artefactual changes would likely lead to the most affected genes being the erroneous focus of research. The findings are likely relevant to all archival collections of ER+ breast cancer.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JNCI Cancer Spectr Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JNCI Cancer Spectr Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido